GLP1R and thyroid cancer: Notably, in a recent nested case-control study using data from a French national health care insurance system, the use of GLP-1 RA by adults with T2D was associated with increased risk of all thyroid cancer (adjusted hazard ratio 1.58, 95% CI 1.27–1.95) and medullary thyroid cancer (adjusted hazard ratio 1.75, 95% CI 1.04–3.05) [118].